Alcon acquires Neurotech and Encelto, the only FDA-approved treatment for MacTel type 2
ALC•Alcon will pay $550 million to acquire Neurotech Pharmaceuticals and Encelto, with possible additional commercial milestone payments; it expects the deal to modestly boost net sales growth and slightly dilute core diluted EPS in 2027, then be accretive after 2027.
1. Acquisition terms
Alcon said it will pay $550 million to acquire Neurotech Pharmaceuticals and Encelto, the only FDA-approved treatment for MacTel type 2. The deal may include additional contingent payments tied to commercial milestones.
2. Financial outlook
Alcon expects the transaction to be modestly accretive to net sales growth and slightly dilutive to core diluted EPS in 2027, and accretive after 2027.
